These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 19804254)

  • 21. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].
    FIELD Study Investigators
    Cardiovasc Diabetol; 2004 Dec; 3():9. PubMed ID: 15571637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
    Wierzbicki AS
    Curr Opin Cardiol; 2009 Jul; 24(4):372-9. PubMed ID: 19424060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials and lipid guidelines for type II diabetes.
    Prisant LM
    J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
    Davidson MH
    Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia.
    Ducobu J; VanHaelst L; Salomon H
    J Cardiovasc Pharmacol; 2003 Jan; 41(1):60-7. PubMed ID: 12500022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
    Wierzbicki AS
    Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of diabetic dyslipoproteinemia.
    Steinmetz A
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of fibrates in the metabolic syndrome: A review.
    Shipman KE; Strange RC; Ramachandran S
    World J Diabetes; 2016 Mar; 7(5):74-88. PubMed ID: 26981181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.
    Hermans MP; Fruchart JC
    Ther Adv Chronic Dis; 2011 Sep; 2(5):307-23. PubMed ID: 23251757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.
    Malur P; Menezes A; DiNicolantonio JJ; O'Keefe JH; Lavie CJ
    Mo Med; 2017; 114(6):464-471. PubMed ID: 30228666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.
    Hermans MP
    Curr Cardiol Rev; 2010 May; 6(2):112-8. PubMed ID: 21532777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-atherogenic effects of fibrates in type 2 diabetes.
    Barter P
    Curr Control Trials Cardiovasc Med; 2001; 2(5):218-220. PubMed ID: 11806800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.